Ubrelvy (Ubrogepant) - Oral

What Is Ubrelvy?

Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist used to treat migraines in adults. It does not prevent migraines from occurring but helps treat acute migraine attacks.

CGRP is a protein present in neurons in the trigeminal ganglion (part of the trigeminal nerve) that causes pain and inflammation. During a migraine attack, CGRP is present at higher levels than usual. Ubrelvy improves migraine symptoms by blocking the activity of CGRP.

This medication is available by prescription as an oral tablet.

Drug Facts

Generic Name: Ubrogepant

Brand Name(s): Ubrelvy

Drug Availability: Prescription

Therapeutic Classification: Antimigraine

Available Generically: No

Controlled Substance: No

Administration Route: Oral

Active Ingredient: Ubrogepant

Dosage Form(s): Tablet

What Is Ubrelvy Used For?

The Food and Drug Administration (FDA) approved Ubrelvy to treat acute migraine with or without aura in adults. Generally, typical migraine symptoms can include:

  • Severe headache
  • Neck or shoulder pain
  • Nausea
  • Inability to tolerate light or sounds
  • Vomiting

Migraines with aura are different from other migraines in that they are characterized by visual or sensory disturbances before the migraine starts.

Ubrelvy should not be used as a preventative treatment of migraines. The safety and efficacy of Ubrelvy have not been established in children and adolescents.

How to Take Ubrelvy

Take Ubrelvy with or without food. It is important to take Ubrelvy at the first signs of migraine. Most people can take a second tablet two hours later if migraine symptoms have not resolved, but do not exceed two tablets within a 24-hour period.

While taking Ubrelvy, keep track of how often you are taking the medication and when your migraines occur to determine how well the medicine is working.

Storage

Store Ubrelvy tablets at room temperature (between 68 degrees and 77 degrees Fahrenheit), and protect them from light and moisture. 

How Long Does Ubrelvy Take to Work?

After taking Ubrelvy, you can expect some migraine relief within 30 minutes, with the greatest benefit seen about two hours after dosing. If the migraine is still present after two hours, taking a second dose can help.

What Are the Side Effects of Ubrelvy?

This is not a complete list of side effects and others may occur. A healthcare provider can advise you on side effects. If you experience other effects, contact your pharmacist or a healthcare provider. You may report side effects to the FDA at fda.gov/medwatch or 1-800-FDA-1088.

Common Side Effects

The most common side effects of Ubrelvy can include nausea and tiredness.

Report Side Effects

Ubrelvy may cause other side effects. Call your healthcare provider if you have any unusual problems while taking this medication. If you experience a serious side effect, you or your healthcare provider may send a report to the FDA's MedWatch Adverse Event Reporting Program or by phone (800-332-1088).

Dosage: How Much Ubrelvy Should I Take?

Drug Content Provided and Reviewed by IBM Micromedex®

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

  • For oral dosage form (tablets):
    • For migraine headaches:
      • Adults—50 or 100 milligrams (mg) per day, as needed. If your migraine does not go away, or if the migraine comes back after being relieved, another dose may be taken 2 hours after the last dose. Do not take more than 200 mg in any 24-hour period.
      • Children—Use and dose must be determined by your doctor.

Modifications

Safe use of Ubrelvy in pregnancy has not been established, and there are no published reports of its use in pregnancy. The decision to use Ubrelvy while pregnant should include a consideration of the benefits and potential risks to the pregnant person and fetus. 

It is unknown whether Ubrelvy is excreted in human breast milk, and there are no published reports of use during breastfeeding. It is a highly protein-bound drug, so milk levels of the drug are likely low. It is likely OK to take while breastfeeding an older infant, though an alternative drug may be preferred while nursing a preterm or newborn infant.

Clinical trials of Ubrelvy did not include a large number of older adults (aged 65 years and older) to determine if there is a difference in safety or efficacy in this population. In general, older individuals may need to start at the lower dose range.

Missed Dose

Ubrelvy should be taken only when you have a migraine; not on a regular basis. Therefore, missing doses should not be an issue.

Overdose: What Happens If I Take Too Much Ubrelvy?

Overdoses of Ubrelvy should be treated symptomatically. Overdose symptoms are expected to be similar to adverse effects and may include nausea, sedation, fatigue, and dry mouth.

What Happens If I Overdose on Ubrelvy?


If you think you or someone else may have overdosed on Ubrelvy, call your healthcare provider or the Poison Control Center. 

If someone collapses or isn’t breathing after taking Ubrelvy, call 911.

Precautions

Drug Content Provided and Reviewed by IBM Micromedex®

It is very important that your doctor check your progress at regular visits. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it.

Do not use this medicine together with clarithromycin (Biaxin®), itraconazole (Sporanox®), or ketoconazole (Nizoral®). Using these medicines together may cause serious unwanted side effects.

Tell your doctor if you are pregnant or planning to become pregnant during treatment with this medicine.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal (eg, St. John's wort) or vitamin supplements.

What Are Reasons I Shouldn’t Take Ubrelvy?

Do not take Ubrelvy if you are also taking a medication known to be a strong inhibitor of cytochrome P450 3A4 (CYP3A4). These medications include ketoconazole, itraconazole, and clarithromycin, among others.

What Other Medications Interact With Ubrelvy?

Ubrelvy may interact with medications that are known as inhibitors or inducers of CYP3A4.

Drug interactions may occur if you take Ubrelvy with the following:

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, grapefruit juice): These medications result in increased exposure to Ubrelvy and should not be taken together. 
  • Moderate CYP3A4 inhibitors (e.g., verapamil, cyclosporine, ciprofloxacin, fluvoxamine, fluconazole): Moderate CYP3A4 inhibitors increase exposure to Ubrelvy and require a dose adjustment. Therefore, use the lower strength of Ubrelvy and do not take a second dose within 24 hours of the first dose. 
  • Strong CYP3A4 inducers (e.g., rifampin, barbiturates, phenytoin, St. John’s wort): These medications result in lower exposure to Ubrelvy and likely reduce its efficacy. So, if you take strong CYP3A4 inducers, you should use an alternative migraine treatment

What Medications Are Similar?

Ubrelvy is a CGRP receptor antagonist that should not be combined with other CGRP receptor antagonists. This family of medications is also referred to as “Gepants”. Other CGRP receptor antagonists include:

  • Qulipta (atogepant): Approved for migraine prevention
  • Nurtec (rimegepant): May be used for the prevention and acute treatment of migraines

Frequently Asked Questions

  • How does Ubrelvy work?

    Calcitonin gene-related peptide (CGRP) is a protein present in neurons in the trigeminal ganglion that causes pain and inflammation. CGRP is present at higher than usual levels during a migraine attack. Ubrelvy blocks the activity of CGRP, which leads to an improvement in migraine symptoms.

  • What side effects can I expect while taking Ubrelvy?

    The most common side effects of Ubrelvy are nausea and drowsiness.

  • How does the efficacy of Ubrelvy compare to triptans?

    A meta-analysis analyzing 17 trials that compared CGRP antagonists to triptans, another type of migraine treatment, found that triptans were more effective than CGRP antagonists (37.8% pain-free at two hours vs. 28.4%).

  • What is Ubrelvy’s place in therapy?

    Ubrelvy and other CGRP antagonists are a good option for abortive treatment (treatment that stops symptoms) of migraines in people who cannot take triptans, including those with a history of coronary artery disease and stroke.

How Can I Stay Healthy While Taking Ubrelvy?

Keep a headache log after starting Ubrelvy to track how often you are taking it and whether you need a second dose. Do not take more Ubrelvy than recommended by your healthcare provider. Taking medication to treat migraines more than about 10 days per month can lead to medication overuse headaches. 

If you find yourself having headaches frequently, talk to your healthcare provider to see if taking a daily medication like a beta-blocker may be helpful for preventing migraines.

Medical Disclaimer

Verywell Health's drug information is meant for educational purposes only and is not intended to replace medical advice, diagnosis, or treatment from a healthcare provider. Consult your healthcare provider before taking any new medication(s). IBM Watson Micromedex provides some of the drug content, as indicated on the page.


Was this page helpful?
3 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Food and Drug Administration. Ubrelvy  prescribing information.

  2. National Library of Medicine. Ubrogepant.

  3. Ha DK, Kim MJ, Han N, Kwak JH, Baek IH. Comparative efficacy of oral calcitonin-gene-related peptide antagonists for the treatment of acute migraine: updated meta-analysis. Clin Drug Investig. 2021;41(2):119-132. doi:10.1007/s40261-020-00997-1